background aim investing influence ft human cellular humor immune use random control clinic studi esophag cancer patient method actor decent depart enroll two group pathway group convent post host stay host expenditure complex record marker inflammatory immune function measure oper well st rd th day pod include serum level interleukin il creative protein cup globular immunoglobulin g img igm iga lymphocyte subpopul cd lymphocyte ccd ratio result complete found implement decrease length charg p admit reaction base level le intent follow compare significantly higher control howe differ concur improv recovery effect inhibit release factor via system esophagectomi trial register chictrtrc date august 